SUVENPHAR2024-04-012024-06-30 SUVENPHAR2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2024-06-30 SUVENPHAR2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SUVENPHAR2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member SUVENPHAR2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543064 SUVENPHAR NOTLISTED Suven Pharmaceuticals Limited Equity 2024-04-01 2025-03-31 2024-08-09 2024-08-02 INR Crores First quarter 13:05:00 15:22:00 2024-08-09 2024-08-09 Not applicable Single segment Contract Development and Manufacturing Operations (CDMO) 2024-04-01 2024-06-30 Unaudited Consolidated 2306910000.00 181550000.00 2488460000.00 383000000.00 0.00 253030000.00 456220000.00 16000000.00 133970000.00 415470000.00 1657690000.00 830770000.00 0.00 830770000.00 200180000.00 23010000.00 223190000.00 0.00 607580000.00 0.00 0.00 0.00 0.00 607580000.00 5990000.00 613570000.00 0.00 0.00 0.00 0.00 25456500000.00 1 2.39 2.39 0.00 0.00 2.39 2.39 Notes 1. The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 9th August, 2024. The above results have been subjected to limited review by the statutory auditors of the company. 2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3. The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, Inc., USA & Casper Pharma Pvt Ltd, (w.e.f from 22nd April, 2022). 4. The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5. Pursuant to definitive agreements entered by the company with Sapala Organics Private Limited (“Sapala”), the company has acquired 51% of the share capital on a fully diluted basis (i.e., 67.5% of the present equity share capital) of Sapala on 12th July, 2024. 6. The Board of Directors had approved on 29th February, 2024 the Scheme of Amalgamation of Cohance Life Sciences Limited (Transferor Company) into and with Suven Pharmaceuticals Limited. The Company has received observation letter with “no adverse observations” from BSE Limited on 19th July, 2024 and observation letter with “no objection” from the National Stock Exchange of India Limited on 23rd July 2024 respectively in relation to the Scheme of Amalgamation. A joint application by the Transferor Company and Suven Pharmaceuticals for the Scheme of Amalgamation has been filed (by way of e-filing) under Sections 230 to 232 of the Companies Act, 2013 and other applicable provisions before the Hon’ble National Company Law Tribunal (NCLT), Mumbai Bench on 25th July, 2024. The Scheme of Amalgamation remains subject to applicable approvals, including approvals from the respective jurisdictional Hon’ble NCLT, and such other approvals, permissions, and sanctions of regulatory and other authorities, as may be applicable. 7. The board of directors of Suven Pharmaceuticals Limited (“Company”/“Transferee Company”) has approved on 29th February 2024 the scheme of amalgamation of Casper Pharma Private Limited (“Transferor Company”) (a wholly owned subsidiary of the Company) into and with the Company under the provisions of Sections 230 to 232 of the Companies Act, 2013 subject to receipt of applicable approvals including jurisdictional NCLT (“Scheme of Amalgamation”). The Hon’ble NCLT, Mumbai Bench has passed an order dated 14th June, 2024 dispensing with the meetings of equity shareholders, secured creditors and unsecured creditors of both the Transferor Company and the Transferee Company and directed, inter-alia the Transferor Company and the Transferee Company to serve notices through registered post on the concerned regulatory authorities for their objections, if any, to the sanctioning of the Scheme of Amalgamation. 8 The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2024 and published year to date figures up to third quarter of the financial year ended March 31, 2024, which are subject to limited review by the statutory auditors. 9. The corresponding previous period figures have been regrouped/reclassified where ever necessary. 10. The Company has chosen to publish the results in Rupees in Crore w.e.f quarter ended June 30,2024. Accordingly, the previous quarters figures have been rounded off. Manufacturing expenses 270840000.00 Other Expenses 144630000.00 Equity investments through other comprehensive income - net change in fair value 20000.00 20000.00 0.00 Exchange differences on translating the financial statements of foreign operations 440000.00 Exchange differences on translating Investments (carried at FVTOCI) 5530000.00 5970000.00 0.00